Edgewise Therapeutics (EWTX) director trades shares via Rule 10b5-1 plan

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. director Edris Badreddin reported option exercises and related share sales. On January 21, 2026, he exercised multiple stock options for Edgewise common stock at exercise prices ranging from $0.39 to $1.93 per share, converting them into common shares held directly.

The same day, he sold shares of Edgewise common stock in several transactions marked with code "S". These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 24, 2025, at an average sale price of $29.44 per share, with individual trades occurring between $29.00 and $29.77. Following the reported transactions, Badreddin directly owned 19,820 shares of Edgewise common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Edris Badreddin

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		M		13,690	A	$0.39	33,510	D
Common Stock	01/21/2026		M		17,236	A	$0.64	50,746	D
Common Stock	01/21/2026		M		10,463	A	$1.93	61,209	D
Common Stock	01/21/2026		M		66,477	A	$1.93	127,686	D
Common Stock	01/21/2026		M		7,605	A	$0.71	135,291	D
Common Stock	01/21/2026		S(1)		13,690	D	$29.44(2)	121,601	D
Common Stock	01/21/2026		S(1)		17,236	D	$29.44(2)	104,365	D
Common Stock	01/21/2026		S(1)		7,605	D	$29.44(2)	96,760	D
Common Stock	01/21/2026		S(1)		10,463	D	$29.44(2)	86,297	D
Common Stock	01/21/2026		S(1)		66,477	D	$29.44(2)	19,820	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.93	01/21/2026		M			10,463	12/03/2024	12/15/2030	Common Stock	10,463	$0.00	0.00	D
Stock Option (Right to Buy)	$1.93	01/21/2026		M			66,477	02/03/2024	02/03/2031	Common Stock	66,477	$0.00	0.00	D
Stock Option (Right to Buy)	$0.71	01/21/2026		M			7,605	09/02/2024	09/01/2030	Common Stock	7,605	$0.00	0.00	D
Stock Option (Right to Buy)	$0.64	01/21/2026		M			17,236	10/16/2023	11/14/2029	Common Stock	17,236	$0.00	0.00	D
Stock Option (Right to Buy)	$0.39	01/21/2026		M			13,690	03/04/2021	04/26/2028	Common Stock	13,690	$0.00	0.00	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025.

2. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/John R. Moore Attorney-in-Fact for Badreddin Edris	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Edgewise Therapeutics (EWTX) report for Edris Badreddin?

Edgewise Therapeutics reported that director Edris Badreddin exercised multiple stock options for common stock and sold shares of common stock on January 21, 2026. The transactions involved option exercises at strike prices between $0.39 and $1.93 and same-day sales of common shares.

Were the Edgewise Therapeutics (EWTX) insider sales by Edris Badreddin under a Rule 10b5-1 plan?

Yes. The filing states that the sales reported were effected pursuant to a Rule 10b5-1 Plan adopted by Edris Badreddin on September 24, 2025. This indicates the sales followed a pre-established trading plan.

At what prices did Edris Badreddin sell Edgewise Therapeutics (EWTX) shares?

The filing reports an average sale price of $29.44 per share. It explains that the shares were sold in multiple transactions at prices ranging from $29.00 to $29.77 per share.

How many Edgewise Therapeutics (EWTX) shares does Edris Badreddin own after these transactions?

After the reported option exercises and sales on January 21, 2026, Edris Badreddin directly owned 19,820 shares of Edgewise Therapeutics common stock, according to the Form 4.

What types of securities did Edris Badreddin transact in for Edgewise Therapeutics (EWTX)?

The transactions involved both stock options (rights to buy) and common stock. He exercised stock options with exercise prices of $0.39, $0.64, $0.71, and $1.93 and then sold common shares acquired from these options.

Is Edris Badreddin a director or officer of Edgewise Therapeutics (EWTX)?

The Form 4 identifies Edris Badreddin as a director of Edgewise Therapeutics, Inc. and does not list him as an officer or 10% owner.